



The Nifty ended 2.23% down at 11,387.50. It opened on a positive note and nosedived from day's high towards finishing with a huge bearish body candle below 11,550. Needless to say this sell off pushed the benchmark index into a consolidation in the price band of 11,550-11,300. Next support below 11,300 is placed round 11,160 levels.

On the Nifty hourly chart; RSI declined sharply from the overbought zone following the decline in the benchmark index. Chart pattern suggests, it may now get into consolidation in the price band of 11,550-11,300.

Nifty patterns on multiple time frames suggest; it finished off the day with a bearish body candle below 11,550 mark, which may now continue to act as the immediate resistance.

### Nifty Crucial Supports & Resistances-

**Supports- 11300, 11160 Resistances- 11550, 11620**

### Open positional calls-

T+7 Positional Buy-  
|Cash Segment| DCB BANK @ 93-92, TGT- 103, SL- 86

T+7 Positional Buy-  
|Cash Segment| INFRATEL @ 207-205, TGT- 222 , SL- 197

T+10 Positional Buy-  
|Cash Segment| ICICI BANK @ 400-395, TGT- 435, SL- 375

T+10 Positional Buy-  
|Cash Segment| CENTURY TEXTILES @ 337-335, TGT- 375, SL- 315

Key Contents	Page No.
Conference Call	4
Result Analysis	6
Domestic News	7

## Nifty Intraday Chart



## Market in Retrospect

India's benchmark indices witnessed their biggest single-day fall in over a month after tensions between India and China escalated yet again at the Ladakh border.

The NSE Nifty 50 index ended 2.2% lower at 11,387. The broader markets represented by the NIFTY 500 Index ended 2.79% lower, ending at 9372. All indices are ended in lower, on which NIFTY Media was the top loser, losing by 5.84%, followed by NIFTY PSU Bank losing by 4.73%.

ONGC was the top gainer, gaining by 1.99%, followed by TCS and Tata Motors, which gained by 0.84% & 0.28% respectively. Sun Pharma was the top loser, losing by 6.39%, followed by SBI and Eicher Motors, which fell by 5.71% & 5.49% respectively.

The Advance: Decline ratio stood at 284:1664

### Market Turnover (In Crore) 31-08-2020

Name	Last	Previous
NSE Cash	98935.61	72925.21
NSE F&O	2348238.21	1402335.91
BSE Cash	5,098.13	4,298.77
BSE F&O	*NA	560.02

### FII Derivatives Flow (In Crore) 28-08-2020\*

Instrument	Purchase	Sale	Net
Index Future	5301.44	4950.75	350.69
Index Option	177134.31	175739.88	1394.43
Stock Future	15754.84	16562.08	-807.24
Stock Option	4921.24	4673.35	247.89

### Institutional Flow (In Crore) 28-08-2020\*

Institution	Purchase	Sale	Net
FII	6618.88	5614.77	1004.11
DII	5341.40	5884.96	543.56

\*Data not updated till 6:30PM

### NIFTY Top Gainers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
ONGC	1.99	0.86	93193563	15844970
TCS	0.84	0.41	6018160	2594031
Tata Motors	0.28	18.15	160564520	119131800
HDFC Bank	0.12	0.11	19250721	14891620
Wipro	0.28	0.51	20571550	7475161

### NIFTY Top Losers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
Indusind Bank	5.33	19.10	57316982	32934620
Bajaj Finserv	5.43	3.28	1179922	657570
Eicher Motors	5.49	3.88	3087539	4305896
SBI	5.71	5.24	119990567	80599580
Sun Pharma	6.39	2.47	20056911	10575890

### Bulk and Block Deals

<https://www.nseindia.com/products/content/equities/equities/bulk.htm>  
<http://www.bseindia.com/markets/equity/EQReports/BulknBlockDeals.aspx>

## Sensex Intraday Chart



## Market in Detailed (Updated after 4:00 PM)

Indian Indices							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Sensex	38628.29	839.02	2.13	0.44	2.72	19.13	3.47
Nifty	11387.50	260.10	2.23	0.69	2.84	18.86	3.30
BSE M Cap	14661.37	576.77	3.79	2.38	6.56	23.80	8.86
BSE S Cap	14336.18	654.37	4.37	3.49	10.09	31.61	14.37
Nifty MC 100	16682.65	686.40	3.95	2.45	7.83	25.69	6.58
BSE Auto	17685.49	607.29	3.32	1.32	7.25	25.48	12.16
BSE Capgoods	13741.54	534.43	3.74	3.73	7.91	11.41	18.89
BSE FMCG	11348.47	238.28	2.06	3.33	0.85	4.14	2.45
BSE Metal	8833.73	316.45	3.46	3.70	12.88	29.81	3.63
BSE Oil&Gas	13083.32	267.50	2.00	2.12	0.69	10.54	0.61
BSE Healthcare	18387.62	891.20	4.62	4.54	0.56	17.52	42.81
BSE Power	1669.87	65.74	3.79	4.26	8.51	12.71	11.55
BSE Realty	1758.40	86.70	4.70	0.54	11.60	24.58	14.13
BSE ConsDur	22758.48	724.34	3.08	2.03	5.96	19.99	2.83
BSE Bank	26972.91	918.90	3.29	4.16	9.65	21.85	12.85
BSE IT	18055.38	124.14	0.68	1.03	1.07	28.35	11.80

Bond Markets							
Name	Yield	Net Chng	%1D	%5D	%1M	%3M	%1Y
US	0.74	0.02	2.27	12.73	39.63	13.01	50.71
UK	0.31	0.03	7.44	50.97	185.32	48.10	29.64
Brazil	3.64	0.07	1.78	0.90	21.92	27.33	17.30
Japan	0.05	0.01	13.56	88.89	155.00	920.00	118.96
Australia	0.98	0.04	3.73	14.85	20.49	10.96	10.96
India	6.12	0.03	0.42	1.21	4.78	6.16	6.74
Switzerland	0.40	0.02	4.10	18.28	26.02	14.22	60.79
Germany	0.39	0.02	5.62	21.39	26.34	13.65	44.86

Currency							
Name	Rate	Net Chng	%1D	%5D	%1M	%3M	%1Y
INR	73.62	0.22	0.30	0.95	1.62	2.61	3.01
USD Index	92.27	0.10	0.11	1.10	1.15	6.17	6.72
YUAN	6.85	0.02	0.28	1.07	1.89	4.11	4.76
GBP	1.33	0.00	0.28	1.93	1.76	6.59	10.35
EUR	1.19	0.00	0.14	1.12	1.21	7.04	8.66
YEN	105.92	0.55	0.52	0.06	0.09	1.58	0.30

Freight							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Baltic Dry	1488.00	16.00	1.06	0.47	10.22	195.24	37.43
Baltic Dirty	474.00	2.00	0.42	1.86	6.32	33.52	27.74
SG Dubai HY	0.44	0.28	175.00	291.30	153.66	68.35	107.71

Global Indices							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Dow Jones	28653.87	161.60	0.57	2.59	8.42	12.89	8.52
Nasdaq	11695.63	70.29	0.60	3.39	8.84	23.24	46.88
S&P 500	3508.01	23.46	0.67	3.26	7.24	15.23	19.87
FTSE100	5963.57	36.42	0.61	0.64	1.12	1.86	17.26
CAC40	5030.89	25.12	0.50	0.40	5.11	7.08	8.26
DAX	13079.65	36.40	0.28	0.02	6.14	12.80	9.47
Mexico IPC	37794.25	147.06	0.39	0.79	2.09	4.63	11.33
Brazil Bovespa	102142.9	1519.30	1.51	0.61	0.75	16.86	1.00
Russian RTS	1279.51	13.78	1.09	0.17	3.64	4.89	1.08
Japan Nikkei	23139.76	257.11	1.12	0.67	6.59	5.77	11.76
Hang Seng	25177.05	245.01	0.96	1.47	2.37	9.65	2.13
Taiwan Index	12591.45	137.40	1.08	0.44	0.58	15.07	18.59
Shanghai Comp	3395.68	8.13	0.24	0.30	2.59	19.05	17.65
KOSPI	2326.17	27.63	1.17	0.16	3.41	14.61	18.21
Malaysia KLCI	1525.21	29.57	1.90	3.29	4.90	3.53	5.39
Jakarta Comp	5238.49	108.17	2.02	0.73	1.73	10.20	17.22
Philippine SE	5884.18	37.37	0.63	2.02	0.75	0.78	26.26
Thai Exch	1310.66	12.65	0.96	0.49	1.35	2.40	20.80

Indian Indices							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
NYMEX Crude	43.51	0.56	1.30	2.14	8.10	22.65	21.00
BRENT Crude	46.44	0.65	1.42	1.80	5.95	19.34	17.42
Natural Gas	2.64	0.02	0.56	0.99	35.00	27.76	12.23

LME							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Gold(\$/Ounce)	1966.68	1.46	0.07	1.94	0.48	13.64	29.33
Silver(\$/Ounce)	27.91	0.39	1.43	4.85	14.38	56.15	51.81
Aluminium	1764.50	21.00	1.20	2.23	4.70	16.51	2.89
Copper	6697.50	56.75	0.85	2.86	3.20	26.24	18.06
Zinc	2491.25	31.25	1.27	2.48	11.18	28.41	10.31
Lead	1947.00	10.25	0.52	0.13	5.19	20.67	5.67

Agro Commodities							
Name	Price	Net Chng	%1D	%5D	%1M	%3M	%1Y
Coffee	126.35	4.00	3.27	5.47	12.21	22.43	14.50
Cotton	65.85	0.77	1.18	0.05	5.09	14.56	5.73
Sugar	12.60	0.17	1.33	1.79	4.91	15.49	2.25
Wheat	558.25	9.50	1.73	5.78	3.62	4.88	11.37
Soybean	964.25	13.75	1.45	6.46	8.04	13.21	3.54

### **Narayana Hrudayalaya Ltd.**

- The salary structure for doctors has changed from a predominantly fixed cost structure to a mix of fixed and variable pay structure since the last 1-1 and a half years.
- Talent acquisition, particularly doctors is not a problem in metro cities despite lower pay than peers as Narayana provides a large volume base of patients and a serious academic environment at all units.
- Attrition, however, is high in Narayana averaging around 42% for all employees in FY20. Attrition for nurses were higher at 58%.
- Doubtful debts on the books predominantly pertain to various Government schemes. Narayana makes a continual effort to reduce doubtful debts.
- The Company will be very cautious on capex in FY21 because of Covid-19.
- Narayana has no near term plans of starting an insurance business.
- While the Management is not able to share targets for the next 3-5 financial years, it believes that that the Company would be able to deliver robust top-line and bottom-line performances in the said periods.
- Nearly all Narayana hospitals are accepting Covid patients. This is more from a social perspective and Narayana in most cases is covering only the cost of consumables.
- The new hospitals would take some more time to make profits. Dharmshila would be the first hospital to break even, hopefully by mid of next financial year.

### **Fortis Healthcare Ltd**

- The next hearing with respect to the IHH Open Offer is scheduled on 11th September.
- The broad strategy of the Company is to review the portfolio of hospital assets with respect to clinical excellence and aim for the highest level of clinical excellence, identify non-core investments for potential divestments, reactivate capex once the current pandemic is over, look at cost reduction measures. For the diagnostics business the broad strategy would include optimising network expansion in B2B and B2C businesses.
- As of now, it's very difficult to suggest when the Company would resume paying dividends. Dividends would be paid once the Company attains a suitable level of profitability and an optimum capital structure.
- As stated earlier, the Company is managing the current Covid situation by reducing costs, particularly manpower, corporate and administrative overheads and sales and marketing expenses.
- The Company has so far treated 7000 Covid patients and has performed over 3,80,000 RTPCR tests with respect to Covid-19.

### Arvind Ltd

Arvind Ltd reported a consolidated net loss of INR97.31 crore for the first quarter ended June 30, 2020, on account of lower income due to the COVID-19 pandemic. The company had posted a net profit of INR24.39 crore in April-June quarter a year ago. Revenue from operations during the quarter under review stood at INR599.28 crore. It was at INR1,896.45 crore in the year-ago quarter. As a result of the lockdown due to the COVID-19 pandemic, the volumes for the current quarter were impacted. Revenue from operations and profitability decreased due to COVID-19 related market volatility

### NHPC Ltd

NHPC reported consolidated net profit dropped 13.52% to INR855.49 crore on 6.49% rise in revenue from operations to INR2,779.48 crore in Q1 June 2020 over Q1 June 2019. Consolidated profit before tax (PBT) slipped 6.85% to INR1,055.80 crore in Q1 June 2020 as against INR1,133.47 crore in Q1 June 2019. Current tax expense for the quarter tumbled 30.40% at INR207.07 crore as against INR297.53 crore paid in Q1 June 2019. NHPC's primary source of revenue is from generation and sale of hydroelectricity. During the outbreak of COVID-19, the Government of India and State Governments had declared lockdown which have affected business in general. Power supply being an essential service and considering the must-run status for Run-of-the-River (ROR) projects and scheduling to the extent possible by RLDCs in case of ROR with Pondage and Storage Projects, there was no material impact of COVID-19 on the financial performance of the company.

### GNFC

Gujarat Narmada Valley Fertilizers & Chemicals Limited (GNFC) announced its quarterly results on August 31, 2020. Consolidated net revenue in Q1FY21 stood at INR700.23cr, which declined by 42.13% yoy from INR1,209.94cr in Q1FY20. EBITDA stood at negative INR24.25cr in Q1FY21 that decreased by 125.22% yoy. For Q1FY20, it had posted EBITDA of INR96.16cr. EBITDA margin as of Q1FY21 was at negative 3.46% that declined by 11.41% yoy compared to the same quarter, previous year. The consolidated net profit in Q1FY21 came in at INR2.97cr that declined by 95.72% yoy, as compared to Q1FY20, when it had reported profit of INR69.44cr. The net profit margin in Q1FY21 came in at 0.42% that declined by 5.32% yoy. The net profit margin for Q1FY20 was at 5.74%.

### **Biocon Biologics launches Semglee, drug to control high blood sugar, in US**

Biocon Biologics, a subsidiary of Biocon, and Mylan have launched Semglee (insulin glargine injection) in vial and pre-filled pen presentations in the US. The drug helps in controlling high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes. It is not recommended for the treatment of diabetic ketoacidosis. Semglee, which received final approval from the U.S. Food and Drug Administration (USFDA), has an identical amino acid sequence to Sanofi's Lantus and is approved for the same indications. To encourage broad patient access to this important medicine, Mylan is offering Semglee at a wholesale acquisition cost (WAC)[1] of \$147.98 per package of five (5) 3ml pens and \$98.65 per 10ml vial, representing the lowest WAC for any long-acting insulin glargine on the market.

### **Reliance almost doubles retail footprint with acquisition of Future Group**

Reliance Industries Ltd acquisition of debt-strapped Future Group will almost double the footprint of its retail business, which now is valued at up to USD 68 billion. The oil-to-telecom conglomerate announced the acquisition of Future's retail, wholesale, logistics and warehousing units for INR24,713 crore. The deal terms entail a merger of five listed units of Future Group into Future Enterprises Ltd (FEL). Reliance Retail has also proposed to invest INR1,200 crore in FEL preferential equity (6.09 per cent of post-merger equity of FEL) and INR1,600 crore in preferential warrants (option to acquire further 7.05 per cent). The deal increases the retail store footprint of Reliance Retail Ltd, a unit of RIL, from current 28.7 million square feet to 52.5 million sq ft, consolidating its pole position. The deal will allow Reliance Retail to almost double its retail area under operation and increase the store count by 15 per cent.

### **India GDP Contracts A Record 23.9% In April-June Quarter**

The Indian economy contracted by a record 23.9% in the April-June 2021 quarter, as the country went into the lockdown to curb the spread of the Covid-19 virus. India's real GDP fell to 26.9 lakh crore in constant terms, 23.9% lower than a year ago, showed data released by the Ministry of Statistics and Programme Implementation on Monday. Nominal GDP fell to Rs 38.08 lakh crore, 22.6% lower than the same period last year. In gross value added terms, the economy contracted 22.8%. The Covid crisis has brought on India's fourth recession since independence and the first since liberalisation. The economy last contracted in FY80. This is the first contraction since India began releasing GDP growth data on a quarterly basis in 1997-98.

### CORPORATE ACTION BONUS / RIGHTS / STOCK SPLIT / DIVIDEND / FCCB / M&A / WARRANTS ETC.

Company	Details
Kakatiya Cement Sugar & Industries Ltd	Cash dividend of INR3 effective 01-09-2020
Sagar Cements Ltd	Cash dividend of INR2.5 effective 01-09-2020
NIIT Ltd	Cash dividend of INR2 effective 01-09-2020
Jay Bharat Maruti Ltd	Cash dividend of INR1.25 effective 01-09-2020

### Domestic Events

- **Upcoming Result:-** Shree Renuka Sugars, Speciality Restaurants, United Textiles, National Aluminium, ONGC, Arvind Fashions, Coal India, Dish Tv India, Gravity
- India Markit Manufacturing PMI for August 2020.

### Global Events

- China Caixin Manufacturing PMI August 2020.
- Japan Unemployment Rate for July 2020.
- Japan Jibun Bank Manufacturing PMI August 2020.
- The U.S. ISM Manufacturing PMI for August 2020.
- Euro Area Manufacturing PMI August 2020.
- Euro Area Unemployment Rate for July 2020.

Source of News : The content may have been taken from The Economic Times, Business Standard, Business Line, Mint and other leading financial newspapers and financial portals BSE,NSE, Bloomberg, Moneycontrol & others.

### **Analyst Certification:**

We /I, Deepankar Saha & Jaydeb Dey Research Analyst(s) of SMIFS Limited (in short "SMIFS / the Company"), authors and the names subscribed to this Research Report, hereby certify that all of the views expressed in this Research Report accurately reflect our views about the subject issuer(s) or securities and distributed as per SEBI (Research Analysts) Regulations 2014. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this Research Report. It is also confirmed that We/I, the above mentioned Research Analyst(s) of this Research Report have not received any compensation from the subject companies mentioned in the Research Report in the preceding twelve months and do not serve as an officer, director or employee of the subject companies mentioned in the Research Report.

### **Terms & Conditions and Other Disclosures:**

SMIFS Limited is engaged in the business of Stock Broking, Depository Services, Portfolio Management and Distribution of Financial Products. SMIFS Limited is registered as Research Analyst Entity with Securities & Exchange Board of India (SEBI) with Registration Number – INH300001474.

SMIFS and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Research Analysts. SMIFS generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this Research Report have been prepared by SMIFS and are subject to change without any notice. The Research Report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of SMIFS Limited. While we would endeavor to update the information herein on a reasonable basis, SMIFS is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent SMIFS from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or policies of SMIFS, in circumstances where SMIFS might be acting in an advisory capacity to this company, or in certain other circumstances.

This Research Report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This Research Report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Securities as defined in clause (h) of section 2 of the Securities Contract Act, 1956, includes Financial Instruments, Currency and Commodity Derivatives. Though disseminated to all the customers simultaneously, not all customers may receive this Research Report at the same time. SMIFS will not treat recipients as customers by virtue of their receiving this Research Report. Nothing in this Research Report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this Research Report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. SMIFS accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this Research Report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. The information given in this report is as of date of this report and there can be no assurance that future results or events will be consistent with this information. The information provided in this report remains, unless otherwise stated, the copyright of SMIFS. All layout, design, original artwork, concepts and intellectual Properties remains the property and copyright of SMIFS and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the SMIFS.



SMIFS shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of SMIFS to present the data. In no event shall SMIFS be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the SMIFS through this report.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (a) Exchange Rates can be volatile and are subject to large fluctuations; (b) the value of currencies may be affected by numerous market factors, including world and notional economic, political and regulatory events, events in Equity & Debt Markets and changes in interest rates; and (c) Currencies may be subject to devaluation or government imposed Exchange Controls which could affect the value of the Currency. Investors in securities such as Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Since associates of SMIFS are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this Research Report.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may: (i) from time to time may have long or short positions in, and buy or sell the Securities, mentioned herein or (ii) be engaged in any other transaction involving such Securities and earn brokerage or other compensation or act as a market maker in the Financial Instruments of the Subject Company/ companies mentioned herein or act as an Advisor or Lender/Borrower to such Companies or have other potential/material Conflict of Interest with respect to any recommendation and related information and opinions at the time of the publication of the Research Report. Or at the time of Public Appearance. SMIFS does not have proprietary trades but may at a future date, may opt for the same with prior intimation to Clients/ Investors and extant Authorities where it may have proprietary long/ short position in the above Scrip(s) and therefore should be considered as interested. The views provided herein are general in nature and do not consider Risk Appetite or Investment Objective of any particular Investor; Clients/ Readers/ Subscribers of this Research Report are requested to take independent professional advice before investing. The information provided herein should not be construed as invitation or solicitation to do business with SMIFS.

SMIFS or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the Research Report as of the last day of the month preceding the publication of the Research Report.

SMIFS encourages independence in Research Report preparation and strives to minimize conflict in preparation of Research Report. Accordingly, neither SMIFS and their Associates nor the Research Analysts and their relatives have any material conflict of interest at the time of publication of this Research Report or at the time of the Public Appearance, if any.

SMIFS or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

SMIFS or its associates might have received any compensation from the companies mentioned in the Research Report during the period preceding twelve months from the date of this Research Report for services in respect of managing or co-managing public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction from the subject company.

SMIFS or its associates might have received any compensation for products or services other than investment banking or brokerage services from the subject companies mentioned in the Research Report in the past twelve months.

SMIFS or its associates or its Research Analysts did not receive any compensation or other benefits whatsoever from the subject companies mentioned in the Research Report or third party in connection with preparation of the Research Report.

Compensation of Research Analysts is not based on any specific Investment Banking or Brokerage Service Transactions.

The Research Analysts might have served as an officer, director or employee of the subject company.

Neither the Research Analysts nor SMIFS have been engaged in market making activity for the companies mentioned in the Research Report.

SMIFS may have issued other Research Reports that are inconsistent with and reach different conclusion from the information presented in this Research Report.

A graph of daily closing prices of the securities/commodities is also available at [www.nseindia.com](http://www.nseindia.com) and/or [www.bseindia.com](http://www.bseindia.com), [www.mcxindia.com](http://www.mcxindia.com) and/or [www.icex.com](http://www.icex.com).

SMIFS submit' s that no material disciplinary action has been taken on the Company by any Regulatory Authority impacting Equity Research Analysis activities in last 3 years.

This Research Report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SMIFS and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

For queries related to compliance of the report, please contact: -

**Sudipto Datta, Compliance Officer**

**SMIFS Limited.**

**Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.**

**Contact No.: +91 33 4011 5414 /91 33 6634 5414**

**Email Id.: [compliance@smifs.com](mailto:compliance@smifs.com)**

**Website: [www.smifs.com](http://www.smifs.com)**